The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma.
It has long been known that certain immune augmenting therapeutics, particularly interferon alpha, can exert profound salutary effects on the clinical progress of patients with cutaneous T-cell lymphoma. Emerging evidence that the host immune response may play an important role in the control of this disorder has led to the clinical application of other cytokines including interleukin-12 and interferon gamma. In this review, the authors will summarize current knowledge regarding the use of cytokines, fusion proteins and antibodies for the treatment of cutaneous T-cell lymphoma.
Rook
Alain H
AH
Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. arook@mail.med.upenn.edu
McGinnis
Karen S
KS
Richardson
Stephen K
SK
Budgin
Jeanne B
JB
Wysocka
Maria
M
Benoit
Bernice M
BM
Hopkins
Jacqueline M J
JM
Vittorio
Carmela C
CC
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007372:Interferons / Q000627:therapeutic use*; D007378:Interleukins / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007378:Interleukins; D007372:Interferons